Literature DB >> 21263096

How genetically engineered mouse tumor models provide insights into human cancers.

Katerina Politi1, William Pao.   

Abstract

Genetically engineered mouse models (GEMMs) of human cancer were first created nearly 30 years ago. These early transgenic models demonstrated that mouse cells could be transformed in vivo by expression of an oncogene. A new field emerged, dedicated to generating and using mouse models of human cancer to address a wide variety of questions in cancer biology. The aim of this review is to highlight the contributions of mouse models to the diagnosis and treatment of human cancers. Because of the breadth of the topic, we have selected representative examples of how GEMMs are clinically relevant rather than provided an exhaustive list of experiments. Today, as detailed here, sophisticated mouse models are being created to study many aspects of cancer biology, including but not limited to mechanisms of sensitivity and resistance to drug treatment, oncogene cooperation, early detection, and metastasis. Alternatives to GEMMs, such as chemically induced or spontaneous tumor models, are not discussed in this review.

Entities:  

Mesh:

Year:  2011        PMID: 21263096      PMCID: PMC3731923          DOI: 10.1200/JCO.2010.30.8304

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  87 in total

Review 1.  An RCAS-TVA-based approach to designer mouse models.

Authors:  Sandra Orsulic
Journal:  Mamm Genome       Date:  2002-10       Impact factor: 2.957

2.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.

Authors:  Stella Pelengaris; Michael Khan; Gerard I Evan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

4.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

Authors:  C M D'Cruz; E J Gunther; R B Boxer; J L Hartman; L Sintasath; S E Moody; J D Cox; S I Ha; G K Belka; A Golant; R D Cardiff; L A Chodosh
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

5.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

6.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.

Authors:  Edward J Gunther; Susan E Moody; George K Belka; Kristina T Hahn; Nathalie Innocent; Katherine D Dugan; Robert D Cardiff; Lewis A Chodosh
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

9.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

10.  Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Authors:  Mohammad Azam; Robert R Latek; George Q Daley
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

View more
  53 in total

1.  Translating cancer 'omics' to improved outcomes.

Authors:  Emily A Vucic; Kelsie L Thu; Keith Robison; Leszek A Rybaczyk; Raj Chari; Carlos E Alvarez; Wan L Lam
Journal:  Genome Res       Date:  2012-02       Impact factor: 9.043

Review 2.  Mouse models of cancer-associated thrombosis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Thromb Res       Date:  2017-12-29       Impact factor: 3.944

3.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

4.  Label-Free Multimodal Multiphoton Intravital Imaging.

Authors:  Jaena Park; Haohua Tu; Marina Marjanovic; Stephen A Boppart
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

6.  Metabolic shifts in residual breast cancer drive tumor recurrence.

Authors:  Kristina M Havas; Vladislava Milchevskaya; Ksenija Radic; Ashna Alladin; Eleni Kafkia; Marta Garcia; Jens Stolte; Bernd Klaus; Nicole Rotmensz; Toby J Gibson; Barbara Burwinkel; Andreas Schneeweiss; Giancarlo Pruneri; Kiran R Patil; Rocio Sotillo; Martin Jechlinger
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

7.  Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.

Authors:  Horacio Cabral; Mami Murakami; Hironori Hojo; Yasuko Terada; Mitsunobu R Kano; Ung-il Chung; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

8.  Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.

Authors:  Antonina Mitrofanova; Alvaro Aytes; Min Zou; Michael M Shen; Cory Abate-Shen; Andrea Califano
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

Review 9.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

10.  Novel murine tumour models depend on strain and route of inoculation.

Authors:  Qiang Fu; Andrew Satterlee; Yongjun Wang; Yuhua Wang; Dun Wang; Jingling Tang; Zhonggui He; Feng Liu
Journal:  Int J Exp Pathol       Date:  2016-07-28       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.